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Abstract The goal of this article is to provide recom-
mendations for the diagnosis and treatment of muscle-in-
vasive and metastatic bladder cancer. The diagnosis of
muscle-invasive bladder cancer is made by pathologic
evaluation after transurethral resection. Recently, a
molecular classification has been proposed. Staging of
muscle-invasive bladder cancer must be done by computed
tomography scans of the chest, abdomen and pelvis and
classified on the basis of UICC system. Radical cystectomy
and lymph node dissection are the treatment of choice. In
muscle-invasive bladder cancer, neoadjuvant chemother-
apy should be recommended in patients with good per-
formance status and no renal function impairment.
Although there is insufficient evidence for use of adjuvant
chemotherapy, its use must be considered when neoadju-
vant therapy had not been administered in high-risk
patients. Multimodality bladder-preserving treatment in
localized disease is an alternative in selected and compliant
patients for whom cystectomy is not considered for clinical
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treatment for patients must be based on cisplatin-contain-
ing combination. Vinflunine is the only drug approved for
use in second line in Europe. Recently, immunotherapy
treatment has demonstrated activity in this setting.
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Introduction
According to GLOBOCAN, about 430,000 new bladder
cancer cases and 165,000 bladder cancer deaths occurred
worldwide in 2012, making it the ninth most common type
of cancer for both gender [1].
Europe has one of the highest incidence rates of bladder
cancer in the world. According to cancer registry data, the
highest incidence rates in men were reported in Southern
Europe, particularly in Spain (age-standardized rate
(ASR) = 36.7 per 100,000) and Italy (ASR = 33.2 per
100,000). In Spain, around 12,200 new cases are diagnosed
every year, with 47 cases per 100,000 men and almost eight
cases per 100,000 women [2].
Overall, bladder cancer mortality has been decreasing
all over the world except in countries undergoing rapid
economic transition [3]. Mortality rates in European men
were by far the highest recorded worldwide (e.g., Spain:
ASR = 8.2 per 100,000).
Smoking is recognized as the most important risk factor
for urothelial bladder cancer (BC) (ever-smokers are con-
sidered to have a 2.5 times higher risk of developing this
tumor than nonsmokers) [3] and is estimated to account for
50% of tumors (former tobacco smoking RR 2.04, 95% CI
1.85–2.25, p\ 0.001; current tobacco smoking RR 3.47,
95% CI 3.07–3.91, p\ 0.001 when compared to never
smokers) [4].
Following smoking, occupational exposure to carcino-
gens, namely aromatic amines, polycyclic aromatic,
hydrocarbons, and chlorinated hydrocarbons is viewed as
the second most important risk factor for urothelial BC.
There are several medical conditions that may predispose
individuals to bladder tumorigenesis: chronic urinary
retention and upper tract dilation increase urothelial
exposure to carcinogens and carcinogenesis associated with
chronic inflammation or schistosomiasis [2].
Methodology
The SEOM guidelines have been developed with the con-
sensus of ten genitourinary cancer oncologists from SEOM
(Spanish Society of Medical Oncology) and SOGUG
(Spanish Oncology Genitourinary Group).
To assign a level of levels of evidence and grades of
recommendation we have used Table 1 [5].
Statements without grading were considered justified
standard clinical practice by the SEOM/SOGUG faculty
and experts.
Molecular biology: molecular classification
Molecular genetic evidence supports the existence of two
distinct pathogenetic pathways for bladder cancer devel-
opment: low-grade papillary superficial tumors (charac-
terized by activation of the receptor tyrosine kinase-Ras
pathway, and activating mutations in the HRAS and
fibroblast growth factor receptor 3 (FGFR3) genes) and
high-grade invasive BC (characterized by alterations in the
p53 and retinoblastoma (RB1) pathways). These genes
interact with the Ras-mitogen-activated protein kinase
(MAPK) signal transduction pathways [6].
Table 1 Levels of evidence/grades of recommendation
Levels of evidence
I Evidence from at least one large randomized, controlled trial of good methodological quality (low potential for bias) or meta-analyses of
well-conducted randomized trials without heterogeneity
II Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or
of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages; optional
D Moderate evidence against efficacy or for adverse outcome, generally not recommended
E Strong evidence against efficacy or for adverse outcome, never recommended
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The variability in outcomes of muscle-invasive bladder
cancer (MIBC) can be explained by differences in the
genetic changes involved in bladder cancer development
and progression. The Cancer Genome Atlas Project com-
pleted one of the most comprehensive molecular analyses
in bladder cancer, examining 131 cases of MIBC [7].
Tumors were histologically categorized and evaluated via
whole genome sequencing, whole exome sequencing, DNA
copy number, complete mRNA and microRNA expression,
DNA methylation, and protein expression and phosphory-
lation. Many genes were consistently mutated, including
TP53, PIK3CA, RB1, FGFR3, and TSC1. In addition, a
few pathways were identified as consistently dysregulated.
Mutations in the p53/RB tumor suppressor pathway were
seen in 93% of tumors, and alterations in the PI3K/AKT/
mTOR and RTK/RAS signaling were seen in 72%. Finally,
alterations that impact epigenetic changes were seen up to
89% of tumors.
In the last few years, several studies have proposed a
molecular classification of bladder cancer based in the
whole genome mRNA expression profiling. The molecular
subtypes identified in bladder cancer have significant
similarities with the molecular classification previously
established in breast cancer patients [8]. A group from the
University of North Carolina classified high-grade bladder
cancer in luminal and basal-like tumors using a 47-gene
signature (BASE 47) [9]. TCGA study [7] defined four
mRNA expression-based subtypes (cluster I–IV). The
cluster I–II correlated with luminal subtype and cluster III–
IV with basal subtype. A third classification proposed by
the MD Anderson group identified basal tumors and seg-
regated the luminal subtype in luminal and p53 like tumors
[10]. In an expanded cohort of 238 TCGA invasive bladder
cancers, four subtypes were identified. Besides luminal and
basal subtypes, two new subtypes were proposed related to
immune cell infiltration termed ‘‘immune undifferentiated’’
and ‘‘luminal immune’’ characterized by the expression of
immune genes (CTLA4 and CD274) [11].
Intrinsic subtypes in MIBC patients are associated with
specific clinical-pathological characteristics. Basal MIBC
are more prevalent in women and are enriched with squa-
mous pathological features, whereas tumors with a
micropapillary histological variant are mainly classified in
the luminal subtype [12] Basal tumors were associated with
advanced disease with poor prognosis. In contrast, luminal
tumors have papillary features that correspond to better
outcome when presented at early stage.
Furthermore, molecular classification according to
gene expression profile can be correlated with bladder
cancer outcome and chemosensitivity. Luminal subtype in
BC patients has been associated with chemoresistance.
Moreover, only a minority of patients with p53 like
tumors responded to neoadjuvant MVAC chemotherapy,
suggesting that patients with this molecular subtype
should be treated with alternative approaches [10]. In
contrast, the greatest benefit of neoadjuvant chemotherapy
has been observed in patients with basal subtype [13]. In
addition, the evidence of immune cell infiltration in
specific bladder cancer subtypes suggests a potential
benefit of immune checkpoint agents in these patients. A
recently published study showed higher efficacy of ate-
zolizumab in advanced bladder cancer patients with the
TCGA luminal cluster II subtype compared with other
subtypes [14]. In conclusion, molecular classification of
bladder cancer can be a useful tool to select the most
adequate therapy for each patient. These advances should
be incorporated into the design of clinical trials and pro-
gressively into the clinical practice.
Diagnosis and staging
The symptom that is most frequently presented is hema-
turia, and irritative urinary symptoms are also common.
Initial diagnosis study is composed of physical exami-
nation, complete tests with hemograma and biochemistry,
cytoscopy, urinary cytology and an image of the upper
urinary tract. The findings of the cytoscopy must be
described in detail, including location, size and number of
injuries. The fluorescent cytoscopy can detect more tumors,
especially in carcinoma in situ and papillary injuries,
therefore it is useful in patients on whom a radiotherapy
treatment is chosen for.
It is followed by bimanual examination under anesthesia
(EUA) and transurethral resection of the bladder (TURBT).
This is important to obtain a pathological diagnosis and for
MIBC in staging, therefore, it is mandatory to include a
representation of the muscular layer. In cases with positive
cytology and a normal cystoscopy, an upper urinary tract
and prosthetic urethra exam must be carried out.
Histological diagnosis is based on the World Health
Organization (WHO) classification [15] and tumor grade is
an important factor to determine the potential progression
and recurrence of the tumor.
In patients with a MIBC confirmed diagnosis, a com-
puted tomography (CT) of chest, abdomen and pelvis, must
be performed as a method of initial staging, including an
excretory-phase CT urography for the upper urinary tract
study, being MRI also an option. Both are useful for local
staging. Routine FDG-PET/CT is not recommended for
routine initial staging on MIBC. Bone scan must be per-
formed if there are bone related symptoms or high levels of
alkaline phosphatase [16].
Staging must be done according to the norms of the
American joint committee on cancer (AJCC) staging
manual 7th edition (Table 2).
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Recommendations
Initial diagnosis study is composed of physical examina-
tion cytoscopy, urinary cytology and an image of the upper
urinary tract, followed by bimanual EUA and TURBT.
Level of evidence 2. Grade of recommendation B.
CT of chest, abdomen and pelvis, must be performed as
a method of initial staging, including an excretory-phase
CT urography for the upper urinary tract study.
Level of evidence: 2. Grade of recommendation B.
Prognostic factors
The relevance of prognosis classifications is to identify
subgroups of patients to decide the most adequate man-
agement for every single patient and should be considered
for stratification for future trials.
Tumor histologic grade and staging have been recog-
nized as significant prognostic factors for recurrence and
progression among patients with nonmetastatic bladder
cancer. In addition, pathological response has been proved
to be prognostic for patients with muscle-invasive bladder
tumors treated with neoadjuvant chemotherapy [17].
At metastatic setting, a prognostic classification was
established for first-line chemotherapy after identifying
two independent prognostic clinical factors: Karnofsky
performance status less than 80% and the presence of
visceral metastases (liver, lung and bone) [18]. Patients can
be classified as good, intermediate or bad prognosis after
the presence of none, one or both factors (median overall
survival: 33, 13.4 and 9.3 months, respectively). This
classification was subsequently validated in another inde-
pendent series from a prospective study [19].
For second-line patients, another prognostic classifica-
tion was proposed [20]. Three independent prognostic
factors in this setting were identified: ECOG performance
status more than 0, hemoglobin value less than 10 g/dL and
the presence of liver metastases. After internal and external
validation, four categories were established from the
presence of none, one, two or three factors with median
survival times of 14.2, 7.3, 3.8, and 1.7 months. Time from
first-line chemotherapy [21] and albumin levels [22] have
also proved independent prognostic significance and
external validation.
At present, no prognostic biomarkers have been vali-
dated for these patients. The indefectible progression after
standard chemotherapy and the introduction of new thera-
peutic approaches deserves further research efforts in this
way.
Recommendations
Use of prognostic classification in first-line chemotherapy.
Level of evidence: II. Grade of recommendation: B.
Use of prognostic classification in second-line
chemotherapy.
Level of evidence: II. Grade of recommendation: B.
Stage II–III treatment
Radical cystectomy
Radical cystectomy (RC) with extended lymphadenec-
tomy, often preceded by neoadjuvant cisplatin-based
chemotherapy, and urinary diversion is the gold standard
definitive surgical treatment MIBC [23] and involves
removal of the bladder, prostate, seminal vesicles, prox-
imal vas deferens and proximal urethra in men, and
bladder, uterus, ovaries, fallopian tubes, urethra and part
of vagina in women. A randomized [24] trial of robotic-
assisted laparoscopic versus open radical cystectomy
showed no difference in morbidity or length of hospital
stay, but longer operative time and increased cost in the
robotic group, similar to results from the CORAL study
[25] from the UK. Forms of urinary diversion include
orthotopic bladder replacement and uretero-ileo-
urethrostomy (Studer and Padovana neobladder) or an
incontinent external ostomy with cutaneous ureter-
oileostomy (Bricker diversion). A glomerular filtration
rate of at least 50 mL/min is mandatory for continent
reservoirs since the kidneys must compensate the meta-
bolic acidosis following incorporation of bowel in the
urinary tract [26]. Candidates for a continent urinary
diversion should also have normal liver function (risk of
hyperammonemia if the reservoir becomes infected), and
should not have undergone any previous major bowel
resection in the ileocecal area (risk of vitamin B12 defi-
ciency) [26].
Three retrospective cohort studies found regional lymph
node dissection to be associated with a lower risk of
mortality compared with no lymph node dissection in
individuals undergoing radical cystectomy for localized
muscle-invasive bladder cancer [27–29]. More extensive
Table 2 TNM staging
TNM staging system [62]
Stage I: T1 N0 M0
Stage II: T2a–T2b N0 M0
Stage III: T3a–T3b, T4a N0 M0
Stage IV: T4b N0 M0
Any T: N1-N3 M0
Any T: Any N M1
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lymph node dissection was associated with a decreased risk
of all-cause or bladder cancer-specific mortality [27]. In
one study, dissection in which ten lymph nodes were
removed was found to be associated with lower 10 year
overall (30.3 vs 39.4%; p\ 0.001) and cancer-specific (38
vs 46%) mortality compared with dissection in which\10
lymph nodes were removed [27].
Recommendations
Radical cystectomy with extended lymphadenectomy is the
gold standard definitive surgical treatment in muscle-in-
vasive bladder cancer.
Level of evidence: III. Grade of recommendation: A.
Neoadjuvant and adjuvant treatment
Although surgery may be curative, a large proportion of
patients will develop recurrence and will ultimately die of
metastatic disease. Several studies have been performed
with perioperative chemotherapy, in both neoadjuvant and
adjuvant settings.
The major impediment to the use of perioperative
chemotherapy in patients with bladder cancer is renal
impairment and comorbidities. Around 50% of patients
have a glomerular filtration rate of less than 60 mL/min,
making them ineligible for cisplatin treatment.
Neoadjuvant treatment
Neoadjuvant chemotherapy has been evaluated in patients
with clinical stage T2-T4aN0M0 MIBC who are candidates
for RC or definitive radiotherapy. The rationale for giving
chemotherapy before cystectomy or full-dose radiation
therapy is to treat micrometastases present at diagnosis, as
approximately 50% of patients diagnosed with MIBC
develop metastatic disease within 2 years.
Cisplatin-based combination chemotherapy provides a
greater survival benefit than surgery alone in two large,
well-designed, randomized trials [17, 30] and two meta-
analyses [31, 32]. Despite a 5% survival benefit at 5 years,
the neoadjuvant approach prior to cystectomy has not been
widely accepted.
The different neoadjuvant regimens have not been
compared in randomized trials, and the ideal cisplatin-
based combination chemotherapy has not been established.
Methotrexate, vinblastine, doxorubicin, and cisplatin
(MVAC) is the best-studied regimen for neoadjuvant
chemotherapy. Dose-dense MVAC (DDMVAC) and
gemcitabine plus cisplatin (GC) regimens have been also
evaluated in several retrospective studies with no sub-
stantive difference in the response rate.
Recommendation
Neoadjuvant chemotherapy is recommended for T2–T4a,
cN0 M0 bladder cancer and should always be cisplatinum-
based combination therapy.
Level of evidence I. Grade of recommendation A.
Neoadjuvant chemotherapy is not recommended for
patients with ECOG PS 2 and/or impaired renal function.
Level of evidence I. Grade of recommendation A.
Adjuvant treatment
An updated meta-analysis of nine randomized trials,
including 945 patients found and overall survival (OS) and
disease-free survival (DFS) benefit among those who
received cisplatin-based adjuvant chemotherapy [33]. For
OS the pooled hazard ratio (HR) across all nine trials was
0.77 (95% CI 0.59–0.99; p = 0.049). On the other hand,
the pooled HR for DFS was 0.66 (95% CI 0.45–0.91;
p = 0.014). This DFS benefit was more apparent among
those with positive nodal involvement (p = 0.010).
All the published trials were prematurely terminated and
all included enrolled less than 100 patients each. Moreover,
two larger randomized clinical trials reported conflicting
results (Spanish trial SOGUG 99/01 that enrolled 142
patients [34] and Italian trial that accrued over 180 patients
[35]). In the SOGUG trial, HR for intention-to-treat pop-
ulation was 0.37 (95% CI 0.64–0.22, p\ 0.0004) favorable
to chemotherapy arm, but the study was prematurely
closed. In the Italian trial was no differences in overall
survival between adjuvant chemotherapy and control group
(48% at 5 years).
In the largest and most recent trial, 284 patients were
randomly assigned to either four cycles of adjuvant
chemotherapy (immediate treatment) or deferred treatment.
The difference in 5-year overall survival was not statisti-
cally significant (53.6 vs 47.7%; HR 0.78, 95% CI
0.56–1.08) [36]. In a post hoc exploratory analysis, overall
survival was significantly improved in those without lymph
node involvement at baseline (79.5 vs 59.0%).
Recommendation
While there is still insufficient evidence for the routine use
of adjuvant chemotherapy in clinical practice, it is likely
that high-risk patients (extravesical and/or node-positive
disease) that have not received neoadjuvant chemotherapy
will benefit most from adjuvant chemotherapy.
Level of evidence I. Grade of recommendation A.
Neoadjuvant chemotherapy should still be preferred due
to a higher level of evidence and better feasibility.
Level of evidence I. Grade of recommendation A.
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Bladder-sparing treatments
Bladder-preserving approaches are reasonable alternatives
to cystectomy for patients who are unfit for surgery and
those who wish to avoid radical surgery.
Clinical criteria helpful in selecting patients for bladder
preservation include small tumors size (B5 cm) without
carcinoma in situ, visible complete TURBT, early tumor
stage (T2–T3a), no hydronephrosis and no metastatic
lymphadenopathy [37].
Options include TURBT alone, TURBT followed by
radiotherapy alone, chemotherapy alone or combination of
chemotherapy and radiotherapy (trimodality treatment).
However, only chemotherapy combined with radiotherapy
has been evaluated in prospective randomized compar-
isons, the other treatment options are still considered to be
investigational.
Trimodality treatment
Trimodality treatment (TMT) include maximal TURBT
followed by radiation (40–45 Gy to the pelvis) with con-
current radiosensitizing chemotherapy and additional
radiation boost to the bladder (20–25 Gy) if complete
response is documented on repeat biopsy. If persistent or
recurrent disease is observed at response evaluation o
during follow-up, salvage cystectomy is recommended.
Three prospective randomized trials have demonstrated
that concurrent chemoradiotherapy is superior to radio-
therapy alone. In a randomized trial of 360 patients,
radiotherapy with concurrent mitomycin C and 5-fluo-
rouracil improved 2 year locoregional disease-free survival
from 54% (radiotherapy alone) to 67%, and 5-year overall
survival from 35 to 48% without increasing grade 3–4
acute or late toxicity [38]. In other study, 99 patients were
randomized to receive radiation with or without cisplatin
and demonstrated an improved local control rate when
cisplatin was given [39]. In the third study, 333 patients
were randomized to receive radiotherapy alone or radio-
therapy plus carbogen and nicotinamide (CON). At
3 years, there was a 13% improvement in overall survival
in favor of combination arm with a 14% lower risk of death
[40]. The optimal combination of radiotherapy and
chemotherapy has not been established.
Neoadjuvant chemotherapy in TMT has not been shown
to improve survival. A phase III trial compared the efficacy
of two cycles of cisplatin, methotrexate and vinblastine
followed by concurrent chemoradiotherapy vs concurrent
chemoradiotherapy alone. No difference in complete clin-
ical response or 5-year overall survival was observed [41].
Results from several prospective trials have demon-
strated the effectiveness of this approach. Five prospective
RTOG trials of TMT in 468 patients demonstrates long
term outcomes with 5 year and 10-year survival rates of 57
and 37%, respectively, 80% of patients retained an intact
bladder at 5 year with low rates of toxicity [42].
Recommendations
TURBT alone or radiotherapy alone cannot be recom-
mended as standard treatment.
Level of evidence: II. Grade of recommendation: B.
Trimodality treatment is an alternative in well- informed
and compliant patients for whom cystectomy is not con-
sidered for clinical or personal reasons.
Level of evidence: I. Grade of recommendation: A.
First-line therapy of locally advanced
and metastatic disease
First-line therapy for ‘‘fit’’ patients
Combination cisplatin-containing chemotherapy is the stan-
dard of care for fit first-line patients with advanced urothelial
carcinoma. Both CG (cisplatin and gemcitabine) and MVAC
(methotrexate, vinblastine, doxorubicin and cisplatin) are
considered as acceptable treatment options in this indication.
There are no clear differences in efficacy between these two
schedules, but toxicity seems to be higher with MVAC. In a
comparative randomized trial [43], median survival and
5-year survivalwere 14 months and 13% forGC, compared to
15.2 months and 15.3% forMVAC.However,CGhas a better
safety profile, with a lower incidence of febrile neutropenia,
oral mucositis and alopecia, and therefore it is usually the
preferred choice for first-line therapy.
High-dose intensity MVAC (HD-MVAC), administered
every twoweeks alongwith GCSF support, allows the delivery
of twice the dose of cisplatin and doxorubicin. Compared with
standard-dose MVAC [44], HD-MVAC showed a higher
complete response rate (21 vs 9%; p = 0.009) and longer PFS
(9.1 vs 8.2 months; p = 0.04), with fewer dose delays and a
better toxicity profile, but without differences in OS. HD-
MVAC should only be considered in selected populations and
in centerswith experience using this schedule, as it has not been
compared with standard CG.
Adding a taxane to standard CG has also been explored
in this setting. The combination of paclitaxel plus CG
(PCG) did not show differences in PFS or OS in a phase III
trial, and toxicity was higher for the triplet [45].
First-line therapy for ‘‘unfit’’ patients
A significant percentage of patients with advanced urothelial
cancer are considered ‘‘unfit’’ for cisplatin-based
chemotherapy, based on the following criteria: Eastern
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Cooperative Oncology Group (ECOG) performance status
(PS) 2 or Karnofsky index 60–70%; creatinine clearance
\60 mL/min; loss of hearing and/or peripheral neuropathy
Cgrade 2 according to theCommonTerminologyCriteria for
Adverse Events version 4.0; orNewYorkHeartAssociations
Class III heart failure [46]. There is no clear standard therapy
for these patients, and the most usual procedure is changing
cisplatin for carboplatin, therefore avoiding renal toxicity
and improving tolerance to the schedule.
A phase II/III trial comparing the activity of carboplatin/
gemcitabine (CaG) with that of carboplatin/methotrexate/
vinblastine (CaMVi) in 178 unfit patients found similar
efficacy for the two regimens [47], with a median OS of 9.3
and 8.1 months, respectively, and with a lower toxicity for
CaG. Someother studies have tested the role of non-platinum
combinations, such as paclitaxel–gemcitabine, which show
encouraging activity, with response rates ranging 40–60%,
but also considerable toxicity. Finally, for frail patients,
monotherapy can also be an option, mainly with paclitaxel,
gemcitabine or vinflunine, but with limited results.
Recommendations
For first-line fit patients, both CG and MVAC are consid-
ered standard options. CG is preferred over MVAC mainly
due to a better safety profile.
Level of evidence: 1. Grade of recommendation: A.
For first-line unfit patients, CaG should be considered
the preferred treatment option.
Level of evidence: 1. Grade of recommendation: A.
Second line
We have limited treatment options for this scenario. Most
of the chemotherapy agents have been tested in phase 2
studies. Paclitaxel, docetaxel, oxaliplatin, pemetrexed, nab-
paclitaxel, ifosfamida, among others, have a response rate
of around 20%, without having proven a global survival
benefit [48]. Combined use of chemotherapy agents
increases the response rate and DFS [49].
Vinflunine, a third generation vinca alkaloid, showed a
benefit in overall survival in eligible population during a
phase 3 study, compared against best supportive care (BSC)
(although not in the intended treatment population) and it has
been approved by the EMA in this indication (IB) [50].
It is recommended, if possible, the inclusion of these
patients in the clinical studies.
Recommendations
For patients who progress after platinum based therapy
offer vinflunine. Treatment in a clinical trial as an
alternative.
Level of evidence I. Grade of recommendation B.
New drugs and immunotherapy agents
Advances in the understanding of themolecular mechanisms
of UBC have led to many studies to evaluate targeted ther-
apies. Potential actionable genomic alterations, including
activatingmutations and RNA expression changes involving
the PI3K/AKT/mTOR and RTK/RAS pathways have been
frequently detected in the TCGA and other studies [7, 11, 51]
Several studies have identified significant activity of targeted
therapies in patients with these genomic alterations. For
example, patients with mutations in PIK3CA (about 17% of
tumors) can be sensitive to PI3K inhibitors, whereas patients
withmutation/amplification of ERBB2 (about 9%of tumors)
or ERBB3 mutations (about 6% of tumors) can respond to
ERBB tyrosine kinase inhibitors, as has been recently
demonstrated [52]. Moreover, inactivating mutations of
genes involved in DNA repair pathways have also been
identified inMIBC patients. Somatic mutations of ERCC2, a
crucial gene of the nucleotide excision repair pathway, were
found in 6–18% of urothelial tumors. These mutations have
been associated with response to neoadjuvant cisplatin-
based chemotherapy in MIBC patients [7, 11, 53, 54].
Immune checkpoint inhibition for cancer treatment is an
area of growing research and recent studies have demon-
strated that upregulation of PD-L1 is an important mecha-
nism of immune escape in NMIBC. Overexpression of PD-
L1 in UC correlates with high-grade disease and worse
clinical outcome. Remarkable efficacy and safety was seen
in a phase I expansion cohort of 67 patients with heavily
pretreated metastatic bladder cancer. Patients received
15 mg/kg of MPDL3280A (atezolizumab), a human mono-
clonal antibody to PD-L1, every 3 weeks. 89 response rates
were reported by PD-L1 positivity status, defined as 5% or
higher of tumor-infiltrating immune cells staining for PD-L1
by IHC [55]. In this study, 27% of tumors were IHC 2- or
3-positive, as defined by expression of PD-L1 on tumor-
infiltrating immune cells. The overall response rate for all
patients by response evaluation criteria in solid tumors
(RECIST) v1.1 was 26%, and was even more remarkable
(43%) among patients with PD-L1? tumor-infiltrating cells.
Even among patients whose tumor-infiltrating immune cells
were PD-L1-, the response rate was 11% as measured by
RECIST v1.1. Themedian time to first response was 42 days
(range 38–85 days). Based on these results, MPDL3280A
received breakthrough designation by the FDA in June 2014.
Recently, several other immunotherapies agents such nivo-
lumab [56], pembrolizumab [57], avelumab [58] or durval-
umab [59] have shown promising data in different phase I/II
trials; and a phase II trial with atezolizumab in platinum-
treated patients showed an ORR 16% (28% IC2/3 PDL1
subgroup) and an overall survival of 7.9 months (11.9 IC2/3
Clin Transl Oncol (2016) 18:1197–1205 1203
123
PDL1 subgroup) [60]. Another multiple PD-1/PDL-1 agents
are currently being tested alone or in combination in
advanced/refractory UC. Many more trials are in develop-
ment in NMIBC.
Follow-up
There is no data about the best follow-up strategy. Because
most recurrences will develop within 24 months, the
approach should be an oncological surveillance more
intensive in this period of time: history, physical exami-
nation, urine cytology, liver and renal function tests, and
electrolytes every 3 months for the first year, every
6 months for the second and third years, and then annually.
CT imaging is reasonably performed every 6 months for
the first 3 years (every 3 months if N? the first year), then
annually to year 5. After year 5 they should be performed
only as clinically indicated [37, 61].
Recommendation
For patients with MIBC a follow-up must be offered.
Level of evidence V. Grade of recommendation B.
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